S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
pixel
Log in
NASDAQ:SRNE

Sorrento Therapeutics Stock Forecast, Price & News

$9.64
-0.34 (-3.41 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.39
Now: $9.64
$9.97
50-Day Range
$6.82
MA: $7.80
$10.03
52-Week Range
$1.55
Now: $9.64
$19.39
Volume13.38 million shs
Average Volume17.22 million shs
Market Capitalization$2.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.7
Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.
Sorrento Therapeutics logo

MarketRank

Overall MarketRank

1.32 out of 5 stars

Medical Sector

663rd out of 1,922 stocks

Biological Products, Except Diagnostic Industry

88th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRNE
CUSIPN/A
Phone858-203-4100
Employees310

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.43 million
Book Value$0.20 per share

Profitability

Net Income$-292,070,000.00
Net Margins-698.01%

Miscellaneous

Market Cap$2.53 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable
$9.64
-0.34 (-3.41 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

How has Sorrento Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Sorrento Therapeutics' stock was trading at $1.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SRNE shares have increased by 421.1% and is now trading at $9.64.
View which stocks have been most impacted by COVID-19
.

Is Sorrento Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sorrento Therapeutics stock.
View analyst ratings for Sorrento Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Sorrento Therapeutics?

Wall Street analysts have given Sorrento Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sorrento Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Sorrento Therapeutics' next earnings date?

Sorrento Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Sorrento Therapeutics
.

How were Sorrento Therapeutics' earnings last quarter?

Sorrento Therapeutics, Inc. (NASDAQ:SRNE) posted its quarterly earnings data on Friday, November, 6th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.08. The biopharmaceutical company had revenue of $11.75 million for the quarter, compared to analysts' expectations of $10.32 million. Sorrento Therapeutics had a negative net margin of 698.01% and a negative trailing twelve-month return on equity of 314.06%.
View Sorrento Therapeutics' earnings history
.

What price target have analysts set for SRNE?

3 equities research analysts have issued 12 month target prices for Sorrento Therapeutics' shares. Their forecasts range from $24.00 to $35.00. On average, they anticipate Sorrento Therapeutics' stock price to reach $29.67 in the next twelve months. This suggests a possible upside of 207.7% from the stock's current price.
View analysts' price targets for Sorrento Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Sorrento Therapeutics' key competitors?

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Advanced Micro Devices (AMD), Moderna (MRNA), NVIDIA (NVDA), ADMA Biologics (ADMA), Tesla (TSLA), Dynavax Technologies (DVAX) and NIO (NIO).

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the following people:
  • Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 56, Pay $794.19k)
  • Mr. Najjam Asghar, Sr. VP & CFO (Age 39)
  • Mr. Brian Sun, Sr. VP, Gen. Counsel & Corp. Sec.
  • Mr. Bill Farley, VP of Sales & Bus. Devel.
  • Dr. Michael A. Royal, SVP & Chief Medical Officer (Age 66)
  • Dr. Alexis Nahama, Sr. VP & Head of RTX Program
  • Dr. Hui Li Ph.D., Sr. VP of ADC BU Leader
  • Dr. Mark R. Brunswick, Sr. VP of Regulatory Affairs
  • Dr. Shawn Sahebi Ph.D., Sr. VP of Strategy & Analytics
  • Mr. Brian Cooley, Sr. VP of Lymphatic Drug Delivery BU Leader

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Donald L. Hagan LLC (0.01%), Spectrum Wealth Advisory Group LLC (0.01%), Kestra Advisory Services LLC (0.01%), Pacer Advisors Inc. (0.01%), Modus Advisors LLC (0.01%) and Lake Street Financial LLC (0.01%).
View institutional ownership trends for Sorrento Therapeutics
.

Which institutional investors are selling Sorrento Therapeutics stock?

SRNE stock was sold by a variety of institutional investors in the last quarter, including Spectrum Wealth Advisory Group LLC.
View insider buying and selling activity for Sorrento Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Sorrento Therapeutics stock?

SRNE stock was bought by a variety of institutional investors in the last quarter, including Kestra Advisory Services LLC, Modus Advisors LLC, Lake Street Financial LLC, Donald L. Hagan LLC, International Assets Investment Management LLC, Pacer Advisors Inc., and Patriot Financial Group Insurance Agency LLC.
View insider buying and selling activity for Sorrento Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $9.64.

How big of a company is Sorrento Therapeutics?

Sorrento Therapeutics has a market capitalization of $2.53 billion and generates $31.43 million in revenue each year. The biopharmaceutical company earns $-292,070,000.00 in net income (profit) each year or ($2.12) on an earnings per share basis. Sorrento Therapeutics employs 310 workers across the globe.

What is Sorrento Therapeutics' official website?

The official website for Sorrento Therapeutics is www.sorrentotherapeutics.com.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.